Prof Wei
Bewersdorf JP et al. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. Blood Advances 2024;8(18):4845-55. Abstract
De Botton S et al. Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. ASCO 2023;Abstract 7012.
Döhner H et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 2024;144(21):2169-73. Abstract
Giessler K et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. Br J Haematol 2024;205(5):1734-45. Abstract
Mrózek K et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia 2023;37:788-98. Abstract
Pollyea DA et al. Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res 2022;28(13):2753-61. Abstract
Récher C et al. Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries. Am J Haem 2024;100(1):23-32. Abstract
Stengel A et al. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: An analysis of 3307 cases. Leukemia 2017;31:705-11. Abstract
Wei AH et al. Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: Subgroup analyses from the phase III QUAZAR AML-001 trial. Hematologica 2023;108(10). Abstract
Zale A et al. A retrospective analysis of intensive chemotherapy vs. venetoclax/hypomethylating agents for patients aged 60-75 with favorable-risk, NPM1-mutated AML. ASH 2024;Abstract 450.
Dr Stone
DiNardo C et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 2022. Abstract
Döhner H et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): A randomised, open-label, multicentre, phase 3 trial. Lancet Hematol 2023;10:e495-509. Abstract
Fernandez HF et al. Anthracycline dose intensification in acute myeloid leukemia. NEJM 2009;361(13):1249-59. Abstract
Hills RK et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15(9):686-96. Abstract
Lancet JE et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Hematol 2021;8(7):e481-91. Abstract
Lancet JE et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36(26):2684-92. Abstract
Lindsley RC et al. Genetic characteristics and outcomes by mutation status in a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (AML). ASH 2019;Abstract 15.
Matthews AH et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 2022;6:3997-4005. Abstract
Othman J et al. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: The UK NCRI AML19 trial. Blood Adv 2023;7(16):4539-49. Abstract
Russell NH et al. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. J Clin Oncol 2024;42(10):1158. Abstract
Dr Perl
Erba HP et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401(10388):1571-83. Abstract
Levis MJ et al. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood Adv 2024;8(10):2527-35. Abstract
Levis MJ et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 2024;42(15):1766-75. Abstract
Levis MJ et al. Post-hoc analysis of measurable residual disease from BMT-CTN 1506/Morpho: FLT3-ITD variant allele frequency and survival are highly correlated. ASH 2023;Abstract 973.
Levis MJ et al. FLT3 inhibitors added to induction therapy induce deeper remissions. Blood 2020;135(1):75-8. Abstract
Perl AE et al. Quantum-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts). ASH 2023;Abstract 832.
Perl AE et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022;139(23):3366-75. Abstract
Perl AE et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019;381(18):1728-40. Abstract
Short NJ et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol 2024;42(13):1499-508. Abstract
Stone RM et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377(5):454-64. Abstract
Dr Stein
Cai SF et. al. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv 2024;8(2):429-40. Abstract
de Botton S et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: A randomized phase 3 trial. Blood 2023;141(2):156-67. Abstract
de Botton S et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv 2023;7(13):3117-27. Abstract
Döhner H et al. Updated survival, blood count recovery and safety results from the Agile study in patients with acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. HemaSphere 2023;7(S3). Abstract
Lachowiez CA et al. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 2023;4(4):276-93. Abstract
Montesinos P et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med 2022;386(16):1519-31. Abstract
Norsworthy KJ et. al. FDA approval summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res 2019;25(11):3205-9. Abstract
Roboz GJ et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood 2020;135(7):463-71. Abstract
Stein EM et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study. Blood 2021;137(13):1792-803. Abstract
Stein EM et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017;130(6):722-31. Abstract
Woods AC et al. FDA approval summary: Olutasidenib for adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 1 mutation. Clin Cancer Res 2024;[Online ahead of print]. Abstract
Dr Wang
Daver N et al. First-in-human phase 1/2 study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia: Updated results from dose escalation. EHA 2024;Abstract S132.
Daver N et al. A phase 1b/2 study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and azacitidine for patients with CD123-positive acute myeloid leukemia. ASH 2021;Abstract 4440.
Issa GC et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol 2024:[Online ahead of print]. Abstract
Jabbour E et al. A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations. ASH 2023;Abstract 57.
Kwon MC et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood 2024;144(11):1206-20. Abstract
Perner F et al. Characterization of acquired resistance mutations to menin inhibitors. AACR 2023;Abstract 3457.
Perner F et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 2023;615:913-9. Abstract
Wang ES et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol 2024;25(10):1310-24. Abstract
Zeidner J et al. Phase 1B study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: Interim results of dose escalation from the BeatAML consortium. EHA 2024;Abstract S134.